Abstract: The present invention relates to a wearable pressure ulcer detection sensor, and the wearable pressure ulcer detection sensor according to the present invention includes a pressure sensor measuring pressure based on a change in capacitance caused by physical force, a temperature sensor measuring temperature based on a change in electrical conductivity due to electron hopping, and an impedance sensor including two electrodes spaced apart from each other and in contact with skin.

Abstract: A wireless communication system, according to one embodiment of the present invention, comprises: a first communication module; and at least one second communication module wirelessly connected to the first communication module, wherein the first communication module is wirelessly connected to the second communication module to which driving power is applied from the same power source as that of the first communication module.

Abstract: The present disclosure relates to a compound represented by Chemical Formula 1, a coating composition including the compound represented by Chemical Formula 1, an organic light emitting device using the same, and a method for manufacturing the same: wherein L1 to L5, R1 to R4, Af1, Af2, Ar1, X1, X2, r1 to r4, m1 to m6, f1 and f2 are described herein.

Abstract: The present disclosure provides a novel compound represented by the following Chemical Formula 1 and an organic light emitting device including the same: wherein L, L?, L1 to L3, Ar1 to Ar3, R1 to R3, n, and a to c are described herein.

Abstract: A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

Abstract: The present application relates to an organic electronic device comprising a first electrode; a second electrode provided opposite to the first electrode; a photoactive layer provided between the first electrode and the second electrode; and an electron transfer layer provided between the photoactive layer and the first electrode, wherein the electron transfer layer comprises a zinc oxide (ZnO) nanoparticle having one or more amine groups bonding to a surface thereof, and a method for manufacturing the same.

Abstract: Provided is a composition for accelerating cell proliferation, including an erythropoietin-derived peptide as an active ingredient. Due to having a simpler structure than that of the existing natural human erythropoietin, the composition easily passes through the tissue-blood barrier, exhibits excellent cell protective activity, does not cause side effects of cell proliferation, and improves a hematopoietic function. Accordingly, the composition is used in the treatment or prevention of an anemic disorder.

Abstract: The present invention relates to a composition for screening ongoing progress of Alzheimer's disease using beta amyloid of a nose discharge sample and a method of screening ongoing progress of Alzheimer's disease using the same, more specifically, to a composition and a kit for screening ongoing progress of Alzheimer's disease, comprising an agent measuring an expression level of a 56 kDa beta amyloid oligomer and a 72 kDa beta amyloid oligomer in an nose discharge sample, and a method of screening ongoing progress of Alzheimer's disease comprising measuring the expression level of the 56 kDa and 72 kDa beta amyloid oligomers in an nose discharge sample.

Abstract: A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

Abstract: The present specification relates to an organic photodiode including: a first electrode; a second electrode provided to face the first electrode; and an organic material layer having one or more layers provided between the first electrode and the second electrode, in which one or more layers of the organic material layer include the compound of Formula 1, and an organic image sensor including the same.

Abstract: The present specification relates to an organic photodiode including: a first electrode; a second electrode provided to face the first electrode; and an organic material layer having one or more layers provided between the first electrode and the second electrode, in which one or more layers of the organic material layer include the compound of Formula 1, and an organic image sensor including the same.

Abstract: The present application relates to an organic electronic device comprising a first electrode; a second electrode provided opposite to the first electrode; a photoactive layer provided between the first electrode and the second electrode; and an electron transfer layer provided between the photoactive layer and the first electrode, wherein the electron transfer layer comprises a zinc oxide (ZnO) nanoparticle having one or more amine groups bonding to a surface thereof, and a method for manufacturing the same.

Abstract: A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

Abstract: The present specification relates to a heterocyclic compound of Formula 1 and an organic photoelectric device including the same.

Abstract: Disclosed are a composition and a method for inducing the de-differentiation of astrocytes into neural stem cells using Nanog. The de-differentiated neural stem cells have the ability to differentiate into astrocytes, neurons, or oligodendrocytes.

Abstract: Disclosed are a composition and a method for inducing the de-differentiation of astrocytes into neural stem cells using Shh. The de-differentiated neural stem cells have the ability to differentiate into astrocytes, neurons, and oligodendrocytes.